Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model.
Identifieur interne : 001969 ( PubMed/Corpus ); précédent : 001968; suivant : 001970Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model.
Auteurs : Hui Hu ; Xianqing Huang ; Ling Tao ; Yi Huang ; Bao-An Cui ; Hanzhong WangSource :
- Vaccine [ 0264-410X ] ; 2009.
English descriptors
- KwdEn :
- Administration, Oral, Animals, Antibodies, Viral (analysis), Antibodies, Viral (biosynthesis), Antibody Formation (immunology), Capsid (immunology), Cell Proliferation, DNA, Viral (genetics), DNA, Viral (immunology), Electroporation, Female, Immunity, Cellular (immunology), Injections, Intramuscular, Interferon-gamma (biosynthesis), Interleukin-4 (biosynthesis), Lymphocytes (immunology), Mice, Mice, Inbred BALB C, Plasmids (immunology), SARS Virus (immunology), Salmonella typhimurium (immunology), Severe Acute Respiratory Syndrome (immunology), Vaccines, Attenuated (immunology), Vaccines, DNA (administration & dosage), Vaccines, DNA (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Vaccines, DNA, Viral Vaccines.
- chemical , analysis : Antibodies, Viral.
- chemical , biosynthesis : Antibodies, Viral, Interferon-gamma, Interleukin-4.
- chemical , genetics : DNA, Viral.
- immunology : Antibody Formation, Capsid, DNA, Viral, Immunity, Cellular, Lymphocytes, Plasmids, SARS Virus, Salmonella typhimurium, Severe Acute Respiratory Syndrome, Vaccines, Attenuated, Vaccines, DNA, Viral Vaccines.
- Administration, Oral, Animals, Cell Proliferation, Electroporation, Female, Injections, Intramuscular, Mice, Mice, Inbred BALB C.
Abstract
The development of strategies to augment the immunogenicity of DNA vaccines is critical for improving their clinical utility. One such strategy involves using the different immune routes with DNA vaccines. In the present study, the immunogenicity of SARS-CoV nucleocapsid DNA vaccine, induced by using the current routine vaccination routes (intramuscularly, by electroporation, or orally using live-attenuated Salmonella typhimurium), was compared in mouse model. The comparison between the three vaccination routes indicated that immunization intramuscularly induced a moderate T cell response and antibody response. Mice administrated by electroporation induced the highest antibody response among the three immunization groups and a mid-level of cellular response. In contrast, the orally DNA vaccine evoked vigorous T cell response and a weak antibody production. These results indicated that the distinct types of immune responses were generated by the different routes of DNA immunization. In addition, our results also show that the delivery of DNA vaccines by electroporation and orally using live-attenuated Salmonella in vivo is an effective method to increase the immune responses. Further studies could be carried out using a combination strategy of both oral and electroporation immunizations to stimulate higher cellular and humoral immune responses.
DOI: 10.1016/j.vaccine.2009.01.021
PubMed: 19186202
Links to Exploration step
pubmed:19186202Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model.</title><author><name sortKey="Hu, Hui" sort="Hu, Hui" uniqKey="Hu H" first="Hui" last="Hu">Hui Hu</name><affiliation><nlm:affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan 430071, PR China. wanghz@wh.iov.cn</nlm:affiliation></affiliation></author><author><name sortKey="Huang, Xianqing" sort="Huang, Xianqing" uniqKey="Huang X" first="Xianqing" last="Huang">Xianqing Huang</name></author><author><name sortKey="Tao, Ling" sort="Tao, Ling" uniqKey="Tao L" first="Ling" last="Tao">Ling Tao</name></author><author><name sortKey="Huang, Yi" sort="Huang, Yi" uniqKey="Huang Y" first="Yi" last="Huang">Yi Huang</name></author><author><name sortKey="Cui, Bao An" sort="Cui, Bao An" uniqKey="Cui B" first="Bao-An" last="Cui">Bao-An Cui</name></author><author><name sortKey="Wang, Hanzhong" sort="Wang, Hanzhong" uniqKey="Wang H" first="Hanzhong" last="Wang">Hanzhong Wang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19186202</idno><idno type="pmid">19186202</idno><idno type="doi">10.1016/j.vaccine.2009.01.021</idno><idno type="wicri:Area/PubMed/Corpus">001969</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001969</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model.</title><author><name sortKey="Hu, Hui" sort="Hu, Hui" uniqKey="Hu H" first="Hui" last="Hu">Hui Hu</name><affiliation><nlm:affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan 430071, PR China. wanghz@wh.iov.cn</nlm:affiliation></affiliation></author><author><name sortKey="Huang, Xianqing" sort="Huang, Xianqing" uniqKey="Huang X" first="Xianqing" last="Huang">Xianqing Huang</name></author><author><name sortKey="Tao, Ling" sort="Tao, Ling" uniqKey="Tao L" first="Ling" last="Tao">Ling Tao</name></author><author><name sortKey="Huang, Yi" sort="Huang, Yi" uniqKey="Huang Y" first="Yi" last="Huang">Yi Huang</name></author><author><name sortKey="Cui, Bao An" sort="Cui, Bao An" uniqKey="Cui B" first="Bao-An" last="Cui">Bao-An Cui</name></author><author><name sortKey="Wang, Hanzhong" sort="Wang, Hanzhong" uniqKey="Wang H" first="Hanzhong" last="Wang">Hanzhong Wang</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Antibodies, Viral (analysis)</term><term>Antibodies, Viral (biosynthesis)</term><term>Antibody Formation (immunology)</term><term>Capsid (immunology)</term><term>Cell Proliferation</term><term>DNA, Viral (genetics)</term><term>DNA, Viral (immunology)</term><term>Electroporation</term><term>Female</term><term>Immunity, Cellular (immunology)</term><term>Injections, Intramuscular</term><term>Interferon-gamma (biosynthesis)</term><term>Interleukin-4 (biosynthesis)</term><term>Lymphocytes (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Plasmids (immunology)</term><term>SARS Virus (immunology)</term><term>Salmonella typhimurium (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Vaccines, Attenuated (immunology)</term><term>Vaccines, DNA (administration & dosage)</term><term>Vaccines, DNA (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term><term>Interferon-gamma</term><term>Interleukin-4</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Formation</term><term>Capsid</term><term>DNA, Viral</term><term>Immunity, Cellular</term><term>Lymphocytes</term><term>Plasmids</term><term>SARS Virus</term><term>Salmonella typhimurium</term><term>Severe Acute Respiratory Syndrome</term><term>Vaccines, Attenuated</term><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Cell Proliferation</term><term>Electroporation</term><term>Female</term><term>Injections, Intramuscular</term><term>Mice</term><term>Mice, Inbred BALB C</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of strategies to augment the immunogenicity of DNA vaccines is critical for improving their clinical utility. One such strategy involves using the different immune routes with DNA vaccines. In the present study, the immunogenicity of SARS-CoV nucleocapsid DNA vaccine, induced by using the current routine vaccination routes (intramuscularly, by electroporation, or orally using live-attenuated Salmonella typhimurium), was compared in mouse model. The comparison between the three vaccination routes indicated that immunization intramuscularly induced a moderate T cell response and antibody response. Mice administrated by electroporation induced the highest antibody response among the three immunization groups and a mid-level of cellular response. In contrast, the orally DNA vaccine evoked vigorous T cell response and a weak antibody production. These results indicated that the distinct types of immune responses were generated by the different routes of DNA immunization. In addition, our results also show that the delivery of DNA vaccines by electroporation and orally using live-attenuated Salmonella in vivo is an effective method to increase the immune responses. Further studies could be carried out using a combination strategy of both oral and electroporation immunizations to stimulate higher cellular and humoral immune responses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19186202</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model.</ArticleTitle><Pagination><MedlinePgn>1758-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2009.01.021</ELocationID><Abstract><AbstractText>The development of strategies to augment the immunogenicity of DNA vaccines is critical for improving their clinical utility. One such strategy involves using the different immune routes with DNA vaccines. In the present study, the immunogenicity of SARS-CoV nucleocapsid DNA vaccine, induced by using the current routine vaccination routes (intramuscularly, by electroporation, or orally using live-attenuated Salmonella typhimurium), was compared in mouse model. The comparison between the three vaccination routes indicated that immunization intramuscularly induced a moderate T cell response and antibody response. Mice administrated by electroporation induced the highest antibody response among the three immunization groups and a mid-level of cellular response. In contrast, the orally DNA vaccine evoked vigorous T cell response and a weak antibody production. These results indicated that the distinct types of immune responses were generated by the different routes of DNA immunization. In addition, our results also show that the delivery of DNA vaccines by electroporation and orally using live-attenuated Salmonella in vivo is an effective method to increase the immune responses. Further studies could be carried out using a combination strategy of both oral and electroporation immunizations to stimulate higher cellular and humoral immune responses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan 430071, PR China. wanghz@wh.iov.cn</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xianqing</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Bao-An</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hanzhong</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018274" MajorTopicYN="N">Electroporation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012486" MajorTopicYN="N">Salmonella typhimurium</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>01</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19186202</ArticleId><ArticleId IdType="pii">S0264-410X(09)00059-0</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2009.01.021</ArticleId><ArticleId IdType="pmc">PMC7115532</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2003 Dec;1(3):209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15035025</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Immun. 1999 Jul;67(7):3674-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10377159</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2005 Mar 25;328(4):979-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15707974</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 1999 Jul 30;227(1-2):85-97</Citation><ArticleIdList><ArticleId IdType="pubmed">10485257</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2269-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15755609</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 May 22;24(21):4503-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16181711</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2000 May 1;164(9):4635-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10779767</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Virol. 2004 Aug;30(4):309-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15163419</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2004 Apr 16;22(13-14):1820-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15068866</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2004 Jul;73(3):338-46</Citation><ArticleIdList><ArticleId IdType="pubmed">15170626</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2007 Jul;14(7):894-901</Citation><ArticleIdList><ArticleId IdType="pubmed">17494640</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2001 Feb 8;19(13-14):1772-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11166903</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vet Microbiol. 2003 Dec 2;97(1-2):31-44</Citation><ArticleIdList><ArticleId IdType="pubmed">14637036</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 9;97(10):5492-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10779556</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 May 8;24(19):4062-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16530298</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunology. 1997 Apr;90(4):618-25</Citation><ArticleIdList><ArticleId IdType="pubmed">9176117</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Feb 20;314(4):931-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14751221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 1996 Dec;46(1-2):111-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9029784</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 2005 Apr;299(1-2):153-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15914198</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2001 Nov 28;80(1-2):75-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11597750</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2004 May 15;38(10):1420-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15156481</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2001 Apr 6;19(20-22):2945-54</Citation><ArticleIdList><ArticleId IdType="pubmed">11282206</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2008 Jan 10;26(2):185-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18054817</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Chem. 2004 Jun;50(6):988-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15054081</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 May;78(9):4638-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15078946</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2004 Jun 23;22(19):2489-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15193413</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2001 Nov 12;20(3-4):623-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11672930</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Diagn Lab Immunol. 2004 Mar;11(2):362-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15013989</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Parasite Immunol. 1987 Mar;9(2):151-60</Citation><ArticleIdList><ArticleId IdType="pubmed">3106921</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2002 May;76(10):4987-99</Citation><ArticleIdList><ArticleId IdType="pubmed">11967315</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2005 Feb 4;327(1):130-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15629440</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 May 22;24(21):4554-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16150517</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Lett. 2004 Apr 15;92(3):237-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15081618</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation><ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vet Immunol Immunopathol. 2002 Nov;90(1-2):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12406655</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>FEMS Immunol Med Microbiol. 2000 Apr;27(4):341-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10727890</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Mar;77(5):2922-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12584316</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1990 Nov;179(1):463-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2171216</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001969 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001969 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19186202
|texte= Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19186202" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |